June 29, 2022

AAV Production System Enables Scalable Gene Therapy Workflows

Thermo Fisher Scientific’s New Gibco AAV-MAX Unaided AAV Production System Helps Reduce Production Costs and Streamline the Transition from Research to Clinical Environments

To address the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the Gibco AAV-MAX Integrated Unaided AAV Production System. This complete and optimized solution simplifies the AAV vector production workflow. The all-in-one AAV-MAX system increases productivity and profitability by delivering high viral titers using Viral Production Cells 2.0, a new clonally documented 293F-derived mammalian cell line.

AAV is crucial for gene therapy; more than 1,300 unique gene therapy products are currently in development, and almost half rely on AAV. The ability to scale production is key to reducing costs and accelerating research to commercialization.

Amy Butler, President of Thermo Fisher’s Biosciences Division, said, “AAV has an efficacy and safety profile that makes it an ideal therapeutic vehicle and one of the go-to biological delivery methods for the latest advances in gene therapy. New AAV production is part of our end-to-end workflow solutions to meet the growing demand for cost-effective and scalable viral vector production Gain access to products and services designed specifically for cell and gene therapy research , with a focus on clinical manufacturing, empowers our biotech and biopharmaceutical partners.”

The AAV-MAX system was developed to go from shake flasks to bioreactors. The system is designed to streamline the transition from research to commercial manufacturing when combined with the active development of regulatory-compliant reagents. On average, the system can save viral vector researchers and developers 25% on plasmid DNA usage and 50% on production costs compared to polyethyleneimine (PEI)-based mammalian production systems ). When used in conjunction with Thermo Fisher’s expanded portfolio of gene therapy products, developers can smoothly transition to commercial production to help deliver therapies to patients.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>